Summary
We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome. The goal of this project is to determine the feasibility of developing these new immunostimulators into an attractive commercial proposition. Establishment of technical feasibility will involve identification the most promising modifications of our drug candidates and testing their efficacy in disease models of cancer and immunization. In addition, we will determine commercial feasibility by conducting market research and competition analysis and by engaging potential industry partners.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/966687 |
| Start date: | 01-09-2021 |
| End date: | 28-02-2023 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome. The goal of this project is to determine the feasibility of developing these new immunostimulators into an attractive commercial proposition. Establishment of technical feasibility will involve identification the most promising modifications of our drug candidates and testing their efficacy in disease models of cancer and immunization. In addition, we will determine commercial feasibility by conducting market research and competition analysis and by engaging potential industry partners.Status
CLOSEDCall topic
ERC-2020-POCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
